Neoplasms

Symptoms and General Pathology

All Conditions

Nervous System Diseases

Neoplasm Metastasis

Brain Neoplasms

Neoplastic Processes

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Antineoplastic Agents

All Drugs and Chemicals

Immune Checkpoint Inhibitors

Temozolomide

Cisplatin

Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group or otherwise into non-local treatment group

Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group or otherwise into non-systemic treatment group

Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group

Participants underwent local treatments such as surgical resection or radiotherapy or surgical resection plus radiotherapy were divided into local treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group

Participants underwent systemic treatments such as chemotherapy or target therapy or chemotherapy plus target therapy were divided into systemic treatment group; Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group

Participants underwent local treatment plus systemic treatment were divided into local treatment+systemic treatment group or otherwise into non-local treatment+systemic treatment group

neurosurgical resection, stereotactic radiosurgery (SRS), whole brain radiotherapy(WBRT), EGFR target drugs, Immune checkpoint inhibitors，cisplatin, temozolomide

neurosurgical resection

The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are:

* What kind of local treatment provides a survival benefit for patients with poor prognostic factors?
* What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors?
* Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors?

Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.

Treatments for Brain Metastases With Poor Prognostic Factors

Effects of Local and Systemic Treatments in Brain Metastases With Poor Prognostic Factors: Multicenter Retrospective Study

We decided not to share the IPD because the study involved a lot of people's privacy

Cancer Hospital of Guangxi Medical University

Guangxi Zhuang Autonomous Region People's Hospital

First Affiliated Hospital of Guangxi Medical University

Sun Yat-sen University

Department of Neurosurgery

Skin and Connective Tissue Diseases

Breast Neoplasms

Recurrence

Breast Diseases

Skin Diseases

Bone Density Conservation Agents

Tamoxifen

Everolimus

Fulvestrant

Exemestane

Aromatase Inhibitors

Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.

Endocrine options included aromatase inhibitors, aromatase inhibitors with CDK4/6 inhibitors, fulvestrant, fulvestrant with CDK4/6 inhibitors, everolimus with exemestane, tamoxifen. For premenopausal women, agents for ovarian function suppression using GnRH agonists or surgical ovarian ablation including bilateral salpingo-oophorectomy are allowed.

Local treatments for metastatic lesions will be added in this group.

Local treatments include modalities described below:

i) Surgical resection: the achievement of tumor-free margin is not obligatory. ii) Stereotactic body radiotherapy iii) Radiofrequency ablation

Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.

Surgical resection

Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57\~97.5Gy/6\~10 Fraction).

Stereotactic body radiotherapy

RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.

Radiofrequency ablation

Sung Gwe Ahn, Ph.D.

Joon Jeong, Ph.D.

Joon Jeong, M.D.,Ph.D.

Sung Gwe Ahn, M.D.

Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.

Local treatment included surgical resection, stereotactic body radiotherapy, palliative radiotherapy, and radiofrequency ablation. Stereotactic body radiotherapy is preferred as a radiation modality.

Endocrine therapies with/without target therapy including CDK4/6 inhibitors or mTOR inhibitors are the mainstay of 1st line treatment for ER-positive/HER2-negative metastatic breast cancer.

Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.

Local treatments for metastatic lesions will be added in this group.

All patients will undergo local treatments in addition to endocrine therapies.

Local treatments include modalities described below:

i) Surgical resection: the achievement of tumor-free margin is not obligatory.

ii) Stereotactic body radiotherapy

iii) Radiofrequency ablation

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Local Treatment in Addition to Endocrine Therapy in ER-positive/HER2-negative Oligo-metastatic Breast Cancer (CLEAR): a Multicentre, Single -Arm, Phase 2 Trial

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Treatments for Brain Metastases With Poor Prognostic Factors	NCT05609162	Brain Metastase...	neurosurgical r...	-	Sun Yat-sen University
Treatments for Brain Metastases With Poor Prognostic Factors	NCT05609162	Brain Metastase...	neurosurgical r...	-	Sun Yat-sen University
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer	NCT03750396	Breast Cancer Recurrent Breas... Stereotactic Bo... Estrogen Recept... Her2-negative T... Surgery	Surgical resect... Stereotactic bo... Radiofrequency ...	20 Years - 75 Years	Gangnam Severance Hospital
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer	NCT03750396	Breast Cancer Recurrent Breas... Stereotactic Bo... Estrogen Recept... Her2-negative T... Surgery	Surgical resect... Stereotactic bo... Radiofrequency ...	20 Years - 75 Years	Gangnam Severance Hospital

Spots Global Cancer Trial Database for local treatments